DNase Treatment for Dry Eyes
| Status: | Recruiting |
|---|---|
| Conditions: | Ocular, Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/17/2018 |
| Start Date: | July 2014 |
| End Date: | September 2018 |
| Contact: | Clinical Trial, Line |
| Email: | mun2@uic.edu |
| Phone: | 312-918-0900 |
Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease
The purpose of this study is to evaluate the tolerability and preliminary efficacy of DNase
eye drops in patients with Sjogren's and Non-Sjogren Dry Eye Disease.
eye drops in patients with Sjogren's and Non-Sjogren Dry Eye Disease.
Inclusion Criteria:
- Aged 18 years or older.
- Capable of giving informed consent and does provide informed consent.
- Documented Dry Eye Disease for at least 6 months.
- Schirmer I <10
- Corneal/ conjunctival (Rose Bengal) staining ≥1
- Ocular symptoms must be considered as annoying or activity limiting (OSDI ≥13; mild).
- Women must be post-menopausal ≥ 1 year, or surgically sterilized. If not, a negative
urine pregnancy test is required within 14 days of receiving her first dose of test
medication (placebo/ study drug) along with definite evidence of contraceptive use
during the duration of the study.
Exclusion Criteria:
- Allergic to Deoxyribonuclease eye drops or any similar products, or excipients of
Deoxyribonuclease eye drops 0.1%.
- Receiving or have received within 30 days any experimental systemic medication.
- Active ocular infection or ocular allergies.
- Any history of eyelid surgery or ocular surgery within the past 3 months.
- Corneal epithelial defect larger than 1 mm2 in either eye.
- The use of topical cyclosporine or corticosteroids within 2 weeks of enrollment
- Have active drug/alcohol dependence or abuse history
We found this trial at
1
site
Chicago, Illinois 60612
Principal Investigator: Sandeep Jain, MD
Phone: 312-355-5220
Click here to add this to my saved trials
